Faron's Insider Split: Senior Advisor Buys 8.94% as New CFO Sells at GBX 182—Whose Move Signals the Real Play?

The real story here isn't in the press release about a new CFO. It's in the filings that show what insiders are actually doing with their own money. The setup is a classic tug-of-war between two key figures.

On one side, we have Timo Syrjälä, a senior advisor, who made a notable move in early March. He increased his stake to the point where he crossed a major holdings threshold, bringing his total to 8.94% of voting rights. This kind of purchase, reported just last week, is a clear signal that someone with close ties to the company sees value at current prices. It's a bet with skin in the game.

On the other side, the new CFO, Jurriaan Dekkers, has already cashed out. He sold 4,000 shares in a transaction dated January 12th, at an average price of GBX 182. That sale price is critical. It was made well above the stock's recent lows. In fact, the company's shares have since hit a new 52-week low, trading as low as GBX 43. Selling at GBX 182 while the stock is now trading at a fraction of that level is a stark contrast to the advisor's purchase.

The thesis is simple: the senior advisor's buying is a notable signal, but it is overshadowed by the new CFO's cash-out. When a newly appointed CFO, bringing a high-profile background from companies like AstraZeneca, sells his initial stake at a premium, it suggests a misalignment of interest. He is taking money off the table early in his tenure, even as the stock price has collapsed. This creates a divided signal. While Syrjälä is putting his money where his mouth is, Dekkers is doing the opposite. For the smart money watching, this isn't a unified 'skin in the game' bet; it's a red flag that the new leadership may not be as bullish as the hype around the company's trials might suggest.

The Clinical Engine: Advancing Trials and the Financial Fuel

The company's clinical engine is running, but the fuel gauge is on empty. The lead asset, bexmarilimab, is in a Phase II trial for relapsed/refractory myelodysplastic syndromes (r/r MDS). A topline readout for that study came in back in April 2025, and the company has since moved to draw down on a convertible bond facility to fund operations ahead of a planned registrational study. This is the clinical progress that insiders and investors are betting on.

Yet the financial fuel is severely strained. The company's capital structure is in distress, with a debt-to-equity ratio of -133.35% and a market cap of just £51.96 million. The most telling signal of cash pressure is the shareholder approval for a rights issue of up to 80 million new shares. This is a classic move for a company with a short financial runway, forcing it to raise capital at depressed prices to avoid a liquidity crunch.

The link between the two is stark. The promising clinical advance-moving toward a registrational study-requires significant funding. But the company's market valuation and balance sheet indicate it has little room for error. The rights issue plan is a direct consequence of that pressure, a necessary step to keep the clinical engine running. For the smart money, this creates a high-risk setup: the potential upside from a successful trial is real, but the immediate financial distress means the company must dilute existing shareholders heavily to get there. The clinical progress is the carrot; the severe financial fuel shortage is the stick forcing a painful capital raise.

The Smart Money's Playbook: Catalysts and What to Watch

The setup is clear. The company is racing toward a critical clinical milestone, but its financial runway is dangerously short. For the smart money, the path forward hinges on a few specific catalysts and the actions of those with skin in the game.

The immediate catalyst is the potential follow-on from the Phase II topline readout. As the company's CEO noted, the convertible bond facility was designed for this exact moment. The Board has already resolved to issue the Second Tranche Bonds, a EUR 10 million convertible note. The smart money will watch for the final drawdown. If it happens, it will be a vote of confidence from the existing investor, Heights Capital Management. If it doesn't, it signals a loss of external support at a time when the company needs it most.

Simultaneously, the rights issue looms. Shareholders approved the plan for up to 80 million new shares, a massive potential dilution. The key metric here is the final allocation. If the company forces existing shareholders to buy more at depressed prices, it will further erode the stock and signal a lack of external confidence. The smart money will scrutinize the final terms for any signs of a rushed or overly dilutive offering.

Most importantly, watch for insider buying from the new CFO or CEO. The senior advisor's purchase is a signal, but it is not enough. The new CFO, Jurriaan Dekkers, has already sold his initial stake at a premium. The absence of any subsequent buying from him or the CEO is a major red flag. In a turnaround, you want to see the new leadership putting their own money on the line. Their silence speaks volumes.

The bottom line is a high-stakes test. The clinical catalyst is real, but the financial fuel shortage is severe. The smart money should watch for the convertible bond drawdown and the final rights issue terms as the next major signals. If those moves proceed without new insider buying, it will likely confirm this as a value trap. If the new leadership steps in with a bet of their own, it could signal a genuine turnaround. For now, the setup is one of high risk and high potential reward, but the financial distress makes the path to reward a long and dilutive one.